Deerfield Management Company, L.P. (Series C) Neurocrine Biosciences Inc Transaction History

Deerfield Management Company, L.P. (Series C)

$4.35 Billion
Q2 2025

A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 1,167,802 shares of NBIX stock, worth $167 Million. This represents 3.38% of its overall portfolio holdings.

Number of Shares

1,167,802

Previous 1,489,000 21.57%

Holding current value

$167 Million

Previous $165 Million 10.87%

% of portfolio

3.38%

Previous 4.17%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$87.54 - $128.18 $28.1 Million - $41.2 Million	-321,198 Reduced 21.57%	1,167,802 $147 Million
Q1 2025 May 15, 2025	BUY	$107.22 - $153.29 $67.2 Million - $96.1 Million	627,000 Added 72.74%	1,489,000 $165 Million
Q4 2024 Feb 14, 2025	SELL	$111.62 - $139.44 $50.7 Million - $63.4 Million	-454,590 Reduced 34.53%	862,000 $118 Million
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $71.7 Million - $95.8 Million	625,586 Added 90.53%	1,316,590 $152 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $26.8 Million - $29.6 Million	-205,715 Reduced 22.94%	691,004 $95.3 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $33.2 Million - $41.6 Million	-312,995 Reduced 25.87%	896,719 $118 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $47.9 Million - $56.1 Million	-535,000 Reduced 30.66%	1,209,714 $114 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $21.8 Million - $28.5 Million	232,000 Added 15.34%	1,744,714 $177 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $46 Million - $53.9 Million	-500,000 Reduced 24.84%	1,512,714 $161 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $26.9 Million - $35.5 Million	354,914 Added 21.41%	2,012,714 $196 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $20.3 Million - $26.5 Million	279,855 Added 20.31%	1,657,800 $155 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $18.8 Million - $25 Million	235,530 Added 20.62%	1,377,945 $117 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $36 Million - $41.3 Million	417,415 Added 57.57%	1,142,415 $110 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $63.5 Million - $86.6 Million	725,000 New	725,000 $70.5 Million

Others Institutions Holding NBIX

# of Institutions

663

Shares Held

102M

Call Options Held

290K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.6B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account

Deerfield Management Company, L.P. (Series C) Neurocrine Biosciences Inc Transaction History